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ABSTRACT
In spite of indisputable benefits, the use of antiretroviral therapy is associated with multiple metabolic com-
plications. Switching to simpler regimens might maintain viral suppression, improve metabolic side effects,
and provide insight into the pathogenesis of these complications. Our objective was to carefully characterize
the virological and metabolic effects of switching from a successful protease inhibitor (PI)-based antiretrovi-
ral regimen to a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen with nevirapine (NVP).
Forty patients, taking their first successful (less than 40 HIV RNA copies/ml) PI-based regimen, switched their
PI to NVP. If patients did not tolerate NVP, substitution with efavirenz was allowed. The duration of the study
was 48 weeks. At 12 weeks intervals subjects had multiple virological and metabolic parameters including
glucose, insulin, C-peptide, glucagon, proinsulin, blood lipids, and lipoproteins. A subgroup of 18 patients also
had body composition evaluations with DEXA scans and MRIs of the abdomen and the thighs as well as in-
sulin tolerance tests. Ninety-five percent of the patients maintained viral suppression (95% CI 88–100%); only
one patient failed and another developed hepatitis. There were improvements in glucose (decreased fasting
glucose, insulin, and improved insulin tolerance) and lipid metabolism (decreased triglycerides and increased
HDL), but no changes in body composition and bone mineral density. Our study supports a pathogenic role




THE CLINICAL BENEFITS IN TERMS OF MORBIDITY AND MOR-TALITY of antiretroviral therapy are incontrovertible. How-
ever, the use of potent antiretroviral therapy is associated with
multiple long-term complications. These include the develop-
ment of insulin resistance and occasionally diabetes,1 lipid ab-
normalities including increases in serum cholesterol and triglyc-
eride levels, abnormalities in the distribution of fat, including
visceral fat accumulation and peripheral fat atrophy, lactic aca-
demia or lactic acidosis, and osteopenia and osteoporosis. Al-
though most of these side effects were initially linked to the
use of protease inhibitors (PIs), it has become apparent that
many factors associated with treatment contribute to the devel-
opment of these problems.2 The specific contribution of each
component of potent antiretroviral regimens is unknown. Fur-
thermore, individual drugs within the same class may be asso-
ciated with different long-term toxicities, as suggested by stud-
ies of single PIs given to HIV-negative subjects.3,4
One possible strategy to maximize the benefits of potent an-
tiretroviral therapy while minimizing the side effects would be
to use certain drug regimens initially, and after a period of time,
when the HIV viral replication is completely suppressed, to
switch to a simpler regimen that might maintain viral suppres-
sion with less metabolic side effects. The original trials using
this approach failed because the “stepping down” regimens
1Washington University School of Medicine, St. Louis, Missouri 63110.
2Regions Hospital, St. Paul, Minnesota 55101.
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were not fully suppressive.5,6 Short-term studies have demon-
strated the maintenance of virological suppression when more
aggressive regimens are used. These have been popularly
termed “switch” studies.7 Initial reports focused on the viro-
logical safety of the strategy. However, careful characterization
of the effects of switching on fasting metabolic parameters and
objective evaluations of body composition is less common. The
purpose of this nonrandomized longitudinal trial, therefore, was
to carefully characterize the virological and metabolic effects
of switching from a successful PI-based antiretroviral regimen
to a nonnucleoside reverse transcriptase inhibitor (NNRTI)-
based regimen with nevirapine (NVP).
MATERIALS AND METHODS
Patients
Eligible patients included those taking their first successful
induction potent antiretroviral therapy with a combination reg-
imen that included any of the approved protease inhibitors, and
who had maintained an undetectable plasma HIV RNA viral
load (400 HIV RNA copies/ml) for at least 6 months. Patients
had to have a viral load 40 HIV RNA copies/ml at the time
of the switch, but were not required to have a metabolic ab-
normality. The study was approved by the IRBs at Washington
University and Regions Hospital. All patients provided written
informed consent.
Objectives
The objectives of the trial were to evaluate the proportion of
subjects who maintained suppression of plasma HIV RNA at
48 weeks after the substitution of the PI in a potent antiretro-
viral combination with NVP and to carefully evaluate the meta-
bolic changes, if any, associated with this substitution.
Study design
All patients discontinued the current PI and started NVP 200
mg/day for 7 days and then 400 mg in two divided doses. Pred-
nisone 40 mg qd was given prophylactically for a week because
of anecdotal reports of decreased frequency of rash in subjects
receiving prednisone. Patients maintained the nucleoside regi-
men they were taking before enrollment in this pilot study. If
patients did not tolerate NVP, substitution with efavirenz (EFV)
was allowed. The anticipated duration of the study was 48
weeks.
Virological/immunological studies
Plasma samples were obtained at the time of the switch and
then every 4 weeks for 48 weeks. Plasma was processed and
assayed in “real time” for HIV RNA using the Roche ultra-
sensitive assay at the Washington University Retrovirology lab.
The limit of quantification of this assay is 40 HIV RNA copies
per ml. CD4 lymphocyte count was monitored every 4 weeks.
Metabolic studies
At baseline, and at 12-week intervals after the switch, patients
had the following fasting endocrine and metabolic parameters as-
sayed: glucose, insulin, C-peptide, glucagon, proinsulin, blood
lipids, and lipoproteins. Metabolic parameters were performed in
batches at a central laboratory (Washington University).
A subset of 18 patients at Washington University also had
whole-body DEXA scans and 1H-MRIs of the abdomen and
thighs at baseline and at 48 weeks to assess body fat distribu-
tion. The MRI images of the abdomen and the lower extremi-
ties were collected in a Siemens 1.5-Tesla whole-body imager.
Adipose tissue area was measured in these images using NIH
Image 1.62c for MacOS. Within a region, fat and muscle tis-
sue were identified by their different pixel intensities. Fat and
muscle areas were quantified by converting their respective
pixel numbers to surface area (cm2). A skilled technician
processed each image to minimize inter- and intrameasurement
variability. Five transverse T1-weighted images of the abdomen
(8 mm thick) at the level of L4 were obtained. Intraabdominal
(visceral) and subcutaneous (SAT) adipose tissue areas were
measured in each of the five images. The results for each im-
age were averaged and expressed as intraabdominal adipose
area to total abdominal adipose area [VAT/(VAT  SAT)]. A
T1-weighted scan was used to acquire eight serial cross-sec-
tional images of both right and left thighs at a position 10 cm
proximal to the lateral condyle of the right tibia. Each cross-
sectional image was 5 mm thick and 5 mm separated each im-
age. NIH Image 1.62c was used to quantify adipose tissue and
muscle cross-sectional area in the right and left thighs. The bone
(femur) cross-sectional area was deleted from the area mea-
surements. The average adipose tissue areas in the eight images
of the right and left thighs are reported separately as [fat
area/(fat  muscle area)]  100.
An Hologic QDR-2000 enhanced-array whole-body DEXA
scanner and software (v5.71A) (Hologic, Waltham, MA) were
used to measure whole-body lean, adipose and bone mass. Cen-
tral to peripheral adipose tissue ratio was calculated as trunk
fat/(right and left arm and leg fat) as previously described.8 Re-
gional array software (v4.74A:1) was used to determine bone
mineral density (BMD) of the whole-body, lumbar spine
(L1–L4), and proximal femur. Each scan was acquired and
processed by a Hologic-certified radiology technologist.
The subjects at the Washington University site also under-
went a 15 min insulin tolerance test every 12 weeks, according
to the previously published method.9 In summary, after an
overnight fast, patients were given an intravenous bolus of 0.05
IU/kg of human insulin (Insulin Actrapid HM, Novo Nordisk,
Mainz, Germany). Blood samples were taken before (0 min),
and at 5, 8, 9, 10, 11, 12, 13, 14, and 15 min after the admin-
istration of insulin for glucose analysis. An index of peripheral
insulin sensitivity was determined from the slope of the decline
in plasma glucose levels from 5 to 15 min (linear regression
analysis). A slope with absolute value 95 mol/liter/min was
an indication of peripheral insulin resistance.
Statistical analysis
Comparisons between categorical groups were done with the
Chi square and the Fisher exact test when appropriate. Mean
values  SE are presented for continuous variables. Paired Stu-
dent’s t test was used to compare continuous variables. All p
values are two tailed. The data were analyzed using the SPSS
software package (SPSS/Sysat, Chicago, IL).
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RESULTS
Baseline characteristics and virology
Figure 1 shows the trial profile and the situation of all pa-
tients at week 48 of the study. Forty patients were enrolled; one
patient was in fact not eligible due to having multiple protease
experience and was excluded from further analysis.
Ninety percent of the patients were men, with a median CD4
cell count at baseline of 511 cells/mm3 (range 140–1329
cells/mm3). The mean baseline body mass index was 26  0.7
kg/m2.
Ninety two percent of the patients were on lamivudine
(3TC)-containing regimens, 46% on zidovudine (ZDV), 46%
on stavudine (D4T), 10% on didanosine (DDI), and only 2%
on abacavir or zalcitabine (DDC). Indinavir (IDV) was the most
common protease (59%), followed by ritonavir/saquinavir
(RTV/SQV) (15%), nelfinavir (NFV) (13%), RTV alone (10%),
and NFV/SQV (2%) in combination.
In general, NVP was well tolerated; six patients (15%) de-
veloped severe rash and switched to EFV. Severe rash was more
frequent among female (3/4, 75%) than in males (3/35, 9%)
(p  0.008). One patient dropped out of the study because of
drug-related hepatitis at week 8. By intent-to-treat analysis of
eligible subjects, the virological success rate of this switch strat-
egy at 48 weeks (defined as 40 copies/ml) was 95% (95% CI
88–100%) while the on-treatment success rate was 97.5% (95%
CI 95–100%). There was one virological failure at week 24 in
a patient whose undetectable viral load was restored after
switching back to a PI-containing regimen.
CD4 T cell counts increased significantly during the dura-
tion of the study from a median count at baseline of 518
cells/mm3 to 608 cells per mm3 (p  0.01).
Metabolic effects of the switch
Glucose metabolism. The average baseline insulin levels
were elevated above 15 IU/ml in 30% of the patients. After
the switch to NVP, there was a decrease in the fasting levels
of glucose, insulin, C-peptide, and glucagon with a trend to-
ward gradual normalization of these values by week 12 (Fig.
2). Fasting glucose tended to decline from 103  9 mg/dl at
baseline to 94  4 mg/dl at week 48, although this difference
did not reach statistical significance (p  0.18). Four of the 15
subjects who underwent an insulin tolerance test at baseline had
evidence of insulin resistance (slope  92 mol/liter/min). All
four of these patients normalized their insulin sensitivity by
week 48 (Fig. 3). One patient who was not insulin resistant at
baseline became insulin resistant during the study. Together
these changes suggest that insulin resistance, one of the hall-
marks of antiretroviral-associated hyperglycemia, improved af-
ter the switch to NVP.
Lipid metabolism. There were no significant changes in to-
tal cholesterol, but the median baseline cholesterol levels were
below 200 mg/dl at baseline. Twenty percent of the subjects
had cholesterol levels above 240 mg/dl at baseline, a propor-
tion that did not change at week 48 (17%). HDL cholesterol in-
creased from 34  2 mg/dl at baseline to 42  2 mg/dl at week
48 (p  0.0001). There was an average decrease in serum
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FIG. 1. Trial profile. Virology/toxicity endpoints. By intent-
to-treat analysis of eligible subjects, the virological success rate
of this switch strategy at 48 weeks (defined as 40 copies/ml)
was 95% (95% CI 88–100%) while the on-treatment success
rate was 97.5% (95% CI 95–100%).
FIG. 2. Effects of switching to NVP on fasting glucose metabolism (mean  SE). There was a trend toward lower glucose and
lower insulin levels at all time points, although it did not reach statistical significance.
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triglycerides (TG) of approximately 80 mg/dl for the whole
group between baseline and week 48. However, the proportion
of individuals with high or very high TG levels (200 mg/dl)
only tended to decrease, from 40% of the cohort at baseline to
37% at week 48 (Fig. 4).
Fat distribution. We did not observe clinically significant
changes in total fat, total lean mass, or central to peripheral fat
ratio measured by DEXA after the switch to NVP (Fig. 5). Per-
cent body fat measured by whole-body DEXA remained stable
after the switch (22  2% vs. 21  2%). The T:A ratio mea-
sured with DEXA at baseline (1.58  0.12) did not improve af-
ter the switch (1.59  0.14). Abdominal fat mass was not
changed significantly (12  1.8 kg at baseline vs. 12  1.3 kg
at week 48). There was a trend toward peripheral fat loss (7%)
over the 48 week follow-up: from 8.3  1.5 kg to 7.6  1.3 kg
(paired t test  0.07). The mean percentage of thigh fat
area/(fat  muscle area) measured by MRI was right thigh 
30  4%; left thigh  33  4% at baseline and right thigh 
33  4%; left thigh  33  4% at week 48 (NS). In the ab-
domen the visceral adipose tissue/total adipose tissue ratio
(VAT:TAT) was 53  4% at baseline vs. 53  5% at week 48
(paired t test, p  0.16). Lean body mass increased 2 kg dur-
ing the 48 weeks from 56  2 kg to 58  2 kg (paired t test 
0.23). Baseline leptin levels (n  17, mean level 3.8  0.6
ng/ml) correlated with appendicular (r  0.84; p  0.0001),
trunk (r  0.81; p  0.0001), and whole-body fat mass (r 
0.86; p  0.0001). However, leptin levels did not change sig-
nificantly after the switch (mean level after the change 4.0 
0.8 ng/ml), reflecting the lack of change in total fat mass.
Bone mineral density (BMD). In agreement with previously
published cohort studies there was a high prevalence of os-
teopenia/osteoporosis in this cohort: 50% had t scores of the
lumbar spine lower than 1. No clear improvements in whole-
body and lumbar spine BMD occurred after 48 weeks of fol-
low-up (BMD in the lumbar spine was 1.00  0.03 g/cm2 at
baseline and 1.02  0.03 g/cm2 after 48 weeks, p  0.14).
DISCUSSION
Potent antiretroviral therapy regimens containing protease in-
hibitors have contributed to declining mortality and morbidity
from HIV-associated immune dysfunction.10 However, in gen-
eral PI-containing regimens are complex, and have been associ-
ated with several metabolic toxicities.11 This has led to a desire
to simplify treatment. NNRTI-containing regimens and the use
of three nucleosides have been shown to be potent in studies of
previously untreated patients. More recently, several studies have
also shown that agents such as efavirenz, nevirapine, and aba-
cavir can effectively replace protease inhibitors in patients in
whom virological suppression is achieved using a PI-based reg-
imen.7 Our study confirms these observations and shows that
nevirapine can be successfully used in place of protease inhibi-
TEBAS ET AL.592
FIG. 3. The effects of switching to NVP on glucose levels
during an intravenous insulin tolerance test (n  15).
FIG. 4. Effects of switching to NVP on serum lipid levels (mean  SE). There were significant reductions in triglyceride lev-
els at all time points (p  0.05), as well as significant increases in HDL cholesterol (p  0.001). Total cholesterol and LDL cho-
lesterol did not change significantly over the 48 week follow-up.
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tors in patients for whom the PI-based regimen was the first po-
tent regimen and who have had plasma HIV RNA levels below
the limit of detection for at least 6 months prior to the switch.
Nevirapine was well tolerated in our study, although we had
an unusually high occurrence of rash. Two different factors
probably contributed to this. The first is the short induction
phase with nevirapine probably led to a greater likelihood of
rash. We originally opted for this 1 week induction instead of
the classic 2 weeks, because of our concerns about low levels
of nevirapine immediately after the discontinuation of protease
inhibitor therapy. Second we added prednisone to prevent the
development of rash. At the time of the design of this study
there were data from nonrandomized cohort studies that sug-
gested a decreased risk of rash in patients taking prednisone
during the initiation of nevirapine therapy.12 Subsequent ran-
domized trials have proven that in fact prednisone increases the
risk of nevirapine-associated rash.13–15 Rash was more frequent
among females, a phenomenon that has already been reported.16
Further studies are needed to understand the mechanism for the
gender-associated differences in nevirapine-associated rash.
Observational studies have suggested that PIs may contrib-
ute to the metabolic abnormalities seen in treated patients, in-
cluding insulin resistance, dyslipidemia, lipoatrophy, central
adiposity, and bone demineralization.1,17,18 We carefully as-
sessed these factors at baseline and during the time on nevi-
rapine and showed that switching from a PI to nevirapine was
associated with an improvement in glucose metabolism, a low-
ering of serum triglycerides, an increase in HDL cholesterol,
but no change in total serum cholesterol levels. It should be
noted that only a minority of the current patients had abnormal
metabolic parameters at baseline, and this may have reduced
our ability to demonstrate significant improvements in these
biochemical parameters. Furthermore, switching to nevirapine
did not reduce visceral fat content or increase thigh subcuta-
neous fat content, at least at the 48 week time point. Lumbar
spine and proximal femur bone mineral densities were not in-
creased at 48 weeks. Improvements in these anthropomorphic
parameters may require a longer period of time. Alternatively,
the PI to NVP switch did not eliminate the factors responsible
for these anthropomorphic complications.
Studies such as this do allow some insights into the poten-
tial role of protease inhibitors in the pathogenesis of these meta-
bolic abnormalities. Abnormalities in glucose metabolism have
been reported in HIV-negative subjects who received indi-
navir,4 and suggest a primary role for this PI in the develop-
ment of insulin resistance and hyperglycemia. Reversal of ab-
normalities in glucose metabolism when the PI is replaced with
NVP (and viremia remains undetectable) supports this conclu-
sion. In a similar manner, ritonavir has been shown to increase
cholesterol and triglyceride levels in HIV-negative subjects.3
Our findings suggest that switching to nevirapine reduces
triglyceride levels and increases HDL-cholesterol levels, but
35–40% of the subjects did not achieve “normal” triglyceride
or HDL cholesterol levels by week 48. Furthermore, in agree-
ment with others7,19 we found no reduction in total cholesterol
after the switch to NVP. Our findings, combined with obser-
vations that HIV infection itself alters lipid metabolism, sug-
gest that the lipid abnormalities seen in treated patients have a
complex pathogenesis, and treatment will therefore be difficult.
The improvement in HDL cholesterol with NVP is interesting
and consistent with recent findings from naive subjects enrolled
in the Atlantic study20 and the 2NN study,21 as well as other
switch studies. Taken together, the findings suggest that long-
term treatment studies assessing the cardiovascular effects of
varying regimens continue to be warranted.
We observed no effect of the switch to NVP on central and
peripheral fat distribution. This is consistent with other switch
studies that involve discontinuing protease inhibitors7 and sug-
gests that the development of either visceral fat gain or pe-
ripheral fat loss is a complex one. Although PIs have been as-
sociated with these changes in observational studies, the failure
to reverse such changes when the PI is discontinued suggests
that the PIs are not required to maintain these effects. This may
suggest that the PIs do not contribute to the pathogenesis of
central fat accumulation or peripheral lipoatrophy. Patients in
our study continued their original nucleoside drugs as a group
had evidence of ongoing peripheral fat loss. Many studies have
implicated nucleosides in the development of lipoatrophy, and
several switch studies have shown that substituting thymidine
analogues can improve lipoatrophy.22
In summary, the switch from PI-based regimens to nevirap-
ine is virologically safe and it is associated with improvements
in some, but not all, metabolic parameters. Our study supports
a pathogenic role for PIs in the development of hypertriglyc-
eridemia and insulin resistance, but perhaps a more limited role
in lipoatrophy.
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FIG. 5. Total, central, and peripheral fat mass measured by
DEXA. There were no significant changes in trunk and whole-
body fat mass. A trend towards peripheral lipoatrophy was
noted: 7% of the peripheral fat was lost (p  0.07).
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